Please login to the form below

Not currently logged in
Email:
Password:

INC Research promotes Jamie Macdonald to CEO

Succession plan will see current CEO James Ogle remain as chairman

INC Research CEO Jamie MacdonaldINC Research has promoted its current chief operating officer Jamie Macdonald to president and CEO.

He will assume his new role at the contract research organisation (CRO) in January, 2013, when he takes over from James Ogle, who will continue to serve as chairman after also serving for nine years as INC's CEO and president.

James Ogle said: "I am proud of our accomplishments during my time at INC Research and the efforts of our many talented employees across the globe who are dedicated in their efforts every day to help our customers bring new life-saving and life-enhancing therapies to market.

"With integration behind us and INC Research solidly positioned for the future as a top-tier CRO, now is the time for me to transition away from the day-to-day leadership of the company and into the role of chairman." 

Macdonald joined INC Research as COO in 2011 as part of the company's acquisition of Kendle, where he served in this same capacity. He has more than 15 years of senior management experience in operational and financial roles in the CRO and biopharmaceutical industries.

Prior to joining Kendle, Jamie served as senior vice president and head of global project management at Quintiles.

Filling Macdonald's empty COO role from January will be Alistair Macdonald, who INC is promoting from president of clinical development services.

He joined INC in 2002 and, prior to his current role, served as head of the company's oncology therapeutic business unit.

21st August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics